Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Author:
Affiliation:
1. Novartis Pharma AG; Novartis Institutes for BioMedical Research; Basel Switzerland
2. Novartis Pharmaceuticals Corporation; East Hanover NJ USA
3. Novartis Pharma AG; Basel Switzerland
Funder
Novartis Pharmaceuticals Corporation
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.876/fullpdf
Reference31 articles.
1. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis;Blauvelt;J Invest Dermatol.,2008
2. Interleukin 17A: toward a new understanding of psoriasis pathogenesis;Lynde;J Am Acad Dermatol.,2014
3. Psoriasis;Nestle;N Engl J Med.,2009
4. Circulating Th17, Th22, and Th1 cells are increased in psoriasis;Kagami;J Invest Dermatol.,2010
5. The IL-23/Th17 axis in the immunopathogenesis of psoriasis;Di Cesare;J Invest Dermatol.,2009
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution;Molecular Pharmaceutics;2024-09-03
2. Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy;JID Innovations;2024-09
3. Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study;Rheumatology and Therapy;2024-06-09
4. Synergizing pharmacometrics and pharmacovigilance for medication error management: the case of secukinumab;European Journal of Clinical Pharmacology;2024-06-01
5. Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies;Rheumatology and Therapy;2024-04-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3